Scholarlink

Introduction <p>Ovarian cancer is the eighth most common cancer among women, accounting for 4.7% of all cancer-related deaths.</p> Objective <p>In this review, we aimed to describe both established and emerging, prognostic and predictive factors.</p> Results <p>Some established prognostic factors are clinical, such as age, ECOG, and Body Mass Index. Histological subtype, stage and grade are also prognostic factors, and optimal surgery is one of the main factors. Furthermore, the presence of ascites at diagnosis and cancer Antigen 125 assessment could help to predict patient outcomes. Nevertheless, median survival is less than 5 years. Among the emerging factors, tumor-infiltrating lymphocytes (TILs) have a proven prognostic value, although their predictive value has not been used in routine practice. Inflammatory response marker ratios, i.e., neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios, could have a prognostic value. Circulating tumor DNA is one of the most promising prognostic and predictive factors. Concerning predictive factors, the main one is homologous recombination deficiency, which is a marker for response to PARP inhibitors and platin-based chemotherapy. The KELIM score is also used to predict chemosensitivity. To be validated in routine practice, other predictive factors require further investigation.</p> Conclusion <p>Despite the poor prognosis in this pathology, some patients are still alive 10 years after diagnosis. A better understanding of this population’s characteristics could help to anticipate patient outcomes and thus adapt their management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Predictive and Prognostic Factors in Epithelial Ovarian Cancer: A Review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年2月11日

查看全文
  • Alexia Giro,
  • Tressie Herrmann,
  • Arthur Bauer,
  • Céleste Pinard,
  • Mélanie Godiveau,
  • Judith Passildas,
  • Catherine Abrial,
  • Xavier Durando

摘要

Introduction

Ovarian cancer is the eighth most common cancer among women, accounting for 4.7% of all cancer-related deaths.

Objective

In this review, we aimed to describe both established and emerging, prognostic and predictive factors.

Results

Some established prognostic factors are clinical, such as age, ECOG, and Body Mass Index. Histological subtype, stage and grade are also prognostic factors, and optimal surgery is one of the main factors. Furthermore, the presence of ascites at diagnosis and cancer Antigen 125 assessment could help to predict patient outcomes. Nevertheless, median survival is less than 5 years. Among the emerging factors, tumor-infiltrating lymphocytes (TILs) have a proven prognostic value, although their predictive value has not been used in routine practice. Inflammatory response marker ratios, i.e., neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios, could have a prognostic value. Circulating tumor DNA is one of the most promising prognostic and predictive factors. Concerning predictive factors, the main one is homologous recombination deficiency, which is a marker for response to PARP inhibitors and platin-based chemotherapy. The KELIM score is also used to predict chemosensitivity. To be validated in routine practice, other predictive factors require further investigation.

Conclusion

Despite the poor prognosis in this pathology, some patients are still alive 10 years after diagnosis. A better understanding of this population’s characteristics could help to anticipate patient outcomes and thus adapt their management.